Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
Amy C. Moore shared on X:
“Ivonescimab is a bispecific Ab targeting both PD1 and VEGF, enhancing binding to both while the linker portion is designed to minimize side effects. It is currently being evaluated against NSCLC, CRC, TNBC.”
Authors: Tingting Zhong, Lingzhi Zhang, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Wenrong Liu, Juan Du, Wen Yin, Na Chen, Jing Min, Michelle Xia,
Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science & Research at the Addario Lung Cancer Medical Institute (ALCMI). She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023